Sandoz
Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim (Zarxio), pegfilgrastim (Ziextenzo) and rituximab, and holds the US application for nelarabine (Arranon).
Overview
Sandoz launched the first US biosimilar (Zarxio, filgrastim-sndz, 2015) and markets biosimilars of pegfilgrastim, rituximab, trastuzumab and denosumab in Europe and the US, as well as a broad generic oncology injectables line.
Scorecard
All companies- approved products +18
- modalities +4
- regions +2
- registry trials +30
Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.
Nelarabine (Arranon) is an infusion for T-cell acute lymphoblastic leukaemia and lymphoma that has come back after at least two other treatments; it is now also added to first-line therapy for children with T-cell leukaemia.
Pegfilgrastim (Neulasta) is a once-per-chemotherapy-cycle injection that boosts white cell recovery and prevents febrile infections; many biosimilar copies now exist and an on-body device can deliver it automatically the day after chemotherapy.
Pages like this
not linked directly; found by shared links- ProductEfbemalenograstim alfa
Shares Pegfilgrastim, Filgrastim (G-CSF).
- TechnologyGrowth factors: G-CSF and febrile neutropenia prevention
Shares Pegfilgrastim, Filgrastim (G-CSF).
- CompanyAmgen
Shares Pegfilgrastim, Filgrastim (G-CSF).